Lizinopril-Teva tab. of 5 mg No. 30

Lizinopril-Tev's tablets are applied at the following indications:

• Arterial hypertension.
• Heart failure.
• Acute myocardial infarction at patients with stable indicators of a hemodynamics (systolic arterial blood pressure> 100 mm Hg.).
• Complication from kidneys in diabetes (treatment of diseases of kidneys at hypertensive patients with diabetes of the II type and an initial nephropathy).

Structure

Active ingredient: lisinopril;

1 tablet contains 5 mg or 10 mg or 20 mg of lisinopril in the form of dihydrate lisinopril;

Excipients: a mannitol (E 421), calcium hydrophosphate, starch corn corn, sodium of a kroskarmelloz, magnesium stearate for tablets on 10 mg and 20 mg ferrous oxide yellow (E172), ferrous oxide black (E172), ferrous oxide red
(E 172).

Contraindication

• Hypersensitivity to lisinopril, to other components of medicament or other APF inhibitors.
• Quincke's disease in the anamnesis (including after use of APF inhibitors, an idiopathic and hereditary Quincke's edema).
• Aortal or mitral stenosis or a hypertrophic cardiomyopathy with the significant hemodynamic disturbances.
• Bilateral renal artery stenosis or stenosis of an artery of the only kidney.
• Acute myocardial infarction with an unstable hemodynamics.
• Cardiogenic shock.
• Patients with creatinine level in blood serum of ≥220 µmol/l.
• Simultaneous use of medicament and high-throughput membranes poliakrilnitrilnatriyu-2-metilosulfonatu (for example, AN69) at urgent dialysis.
• Simultaneous use of the aliskiren-containing medicaments to patients with diabetes or a renal failure (SKF <60 ml/min. / 1.73 m ² ).
• Primary hyper aldosteronism.
• Pregnant women or women who are going to become pregnant.
• Simultaneous use with sakubitrilom/valzartany. Drug treatment of Lizinopril-Tev can be begun only in 36 hours after reception of the last dose of a sakubitrilu/valsartan.

Route of administration

needs to accept Lisinopril orally 1 time a day. As well as other medicaments which it is necessary to accept 1 time a day, lisinopril need to be accepted every day approximately in identical time. Meal does not influence absorption of tablets of lisinopril. The dose needs to be defined individually according to clinical data of the patient and indicators of arterial blood pressure.

Feature of use

Pregnant

It is contraindicated.

Safety and efficiency of use of lisinopril are not established to children by

therefore it is not necessary to appoint medicament of this age category of patients.

Drivers

needs to take possibility of dizziness and increased fatigue into account that can affect ability to run motor transport or other mechanisms.

Overdose

Symptoms: arterial hypotension, circulator shock, electrolytic disturbances, renal failure, hyperventilation, tachycardia, heart consciousness, bradycardia, dizziness, concern and cough.

Treatment: intravenous administration of saline solutions. In arterial hypotension it is necessary to put the patient on a back with raised upside down. If it is possible, appoint infusion of angiotensin II and/or intravenously enter catecholamines. If the medicament is taken recently, washing is shown to a stomach, use of absorbents and sodium of sulfate. For treatment of steady bradycardia the use of a pacemaker is shown.

recommends constant control of laboratory indicators (determination of level of electrolytes and creatinine in blood serum) and vital signs.

from an organism by means of a hemodialysis, at the same time it is necessary to avoid use of polyacrylonitrile metallosulfonatny high-flowing membranes (for example AN69).

in case of a Quincke's disease are appointed by antihistaminic drugs. If the clinical situation is followed by hypostasis of language, a glottis, throat, it is necessary to begin in an urgentny order treatment by transdermalny introduction of 0.3-0.5 ml of solution of adrenaline (1:1000), for ensuring passability of airways the intubation or laryngotomy are shown.

Side effects

• from the system of blood: decrease in level of hemoglobin and hematocrit, oppression of activity of marrow, anemia, thrombocytopenia, leukopenia, neutropenia, agranulocytosis, hemolytic anemia, lymphadenopathy, autoimmune disease.
• from a metabolism: hypoglycemia.
• from the central nervous system: dizziness, headache, change of mood, paresthesia, disturbance of flavoring feelings, sleep disorder, balance disturbance, disorientation, confusion of consciousness, disturbance of a scent, depression symptoms, faint.
• from a cardiovascular system: orthostatic effect (including arterial hypotension), a myocardial infarction or a cerebrovascular stroke, perhaps, secondary because of excessive arterial hypotension at patients of group of high risk, palpitation, tachycardia, Reynaud's phenomenon.
• from a musculoskeletal system: muscular spasms were registered.
• from a respiratory system: cough, bronchitis, rhinitis, short wind, dispnoe, Quincke's disease, bronchospasm, glossitis, sinusitis, allergic alveolitis / eosinophilic pneumonia. Upper respiratory tract infections were registered.
• from a digestive tract: diarrhea, vomiting, nausea, an abdominal pain, dyspepsia, dryness in a mouth, reduction of appetite, change of taste, pancreatitis, an intestinal Quincke's disease, a constipation, hepatitis (hepatocellular or cholestatic), jaundice and a liver failure.
• from skin: rash, sverbezh, hypersensitivity / a Quincke's disease of the face, extremities, lips, language, a glottis and/or throat, feeling of heat, a dermahemia, urticaria, an alopecia, psoriasis, the raised potovydeleniye, a pempigus, a toxic epidermal necrolysis, Stephens-Johnson's syndrome, a polymorphic erythema, a skin lymphocytoma.
to
• It was reported about a syndrome, including one or several symptoms: fever, vasculitis, myalgia, arthralgia/arthritis, emergence of positive antinuclear antibodies, acceleration of blood sedimentation rate, eosinophilia and leukocytosis, rashes, photosensitization or other skin manifestations.
• from an urinary system: renal dysfunction, uraemia, acute renal failure, oliguria/anury.
• from an endocrine system: inadequate secretion of antidiuretic hormone.
• from a reproductive system: impotence, gynecomastia.
• General disturbances: increased fatigue, weakness.

Interaction

Contraindicated simultaneous use of medicament and high-throughput membranes with poliakrilnitrilnatriyu-2-metilosulfonatu (for example AN 69) at urgent dialysis.

APF Inhibitors exponentiate effect of ethanol. Ethanol increases arterial blood pressure, reducing effect of APF inhibitors.

Contraindicated simultaneous use with sakubitrilom/valzartany. Drug treatment of Lizinopril-Tev can be begun only in 36 hours after reception of the last dose of a sakubitrilu/valsartan.

Storage conditions

Drug does not demand special storage conditions.

out of children's reach.

Expiration date - 4 years.